What We're Reading: Bill Targets Maternal Mortality Rates; Cutting Drug Prices; US Biosimilar Adoption
The House has passed a bill that would support state efforts to investigate pregnancy-related deaths and research how to prevent future deaths; a column in The New York Times examined 4 specific drug pricing policies and had 3 health policy experts weigh in on what the outcomes of implementing these policies could be; despite the benefits of using biosimilar filgrastim, the United States has lagged behind other countries in adopting the therapy.
Bipartisan Bill Targets Maternal Mortality Rates
The House has passed a bill introduced by Representatives Jaime Herrera Beutler, R-Washington, and Diana DeGette, D-Colorado, that would support state efforts to investigate pregnancy-related deaths and research how to prevent future deaths.
Experts Weigh In on Policies Targeting Drug Prices
US Lags in Adoption of Biosimilar Filgrastim
A
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025